Ionis Pharma EVP Bennett sells shares worth $2.3m

Ionis Pharmaceuticals (NASDAQ:IONS) Executive Vice President and Chief Scientific Officer, C. Frank Bennett, sold shares of the company’s common stock worth $2.3 million, according to a recent SEC filing. The sales occurred on September 2, 2025, and September 3, 2025, with prices ranging from $49.14 to $60.62. The timing is notable as the stock has surged 39.2% in the past week and is trading near its 52-week high of $62.08. InvestingPro analysis suggests the stock is currently in overbought territory.

On September 2, Bennett sold 5,000 shares at $49.14 per share. Then, on September 3, he sold 33,909 shares with prices ranging from $60.25 to $61.24, and 12,891 shares with prices ranging from $61.26 to $61.995. The transactions come as Ionis, now valued at $9.47 billion, appears overvalued according to InvestingPro Fair Value metrics.

The filing also indicates that on September 3, Bennett exercised options to acquire 46,800 shares of Ionis Pharmaceuticals stock at an exercise price of $53.77. For deeper insights into IONS’s valuation and 12 additional ProTips, visit InvestingPro.

In other recent news, Ionis Pharmaceuticals has reported significant developments that have caught the attention of investors. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, which demonstrated statistically significant benefits in triglyceride lowering and reducing the risk of acute pancreatitis. This news led to a surge of interest from analysts, with H.C. Wainwright raising its price target for Ionis Pharmaceuticals to $95, citing strong triglyceride reductions in the pivotal studies. Similarly, RBC Capital increased its price target to $80, highlighting the potential of Ionis’ acute pancreatitis treatment.

BMO Capital also upgraded Ionis Pharmaceuticals from Market Perform to Outperform, expressing optimism about the drug Olezarsen, which showed better-than-expected benefits for acute pancreatitis. Oppenheimer joined the trend by raising its price target to $81 following the announcement of the positive Phase 3 trial results for Tryngolza in treating severe hypertriglyceridemia. These developments reflect a growing confidence among analysts about the company’s future prospects, driven by its recent clinical successes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.